|Bid||256.99 x 800|
|Ask||256.60 x 900|
|Day's Range||255.25 - 259.23|
|52 Week Range||250.31 - 319.76|
|Beta (5Y Monthly)||0.13|
|PE Ratio (TTM)||14.04|
|Earnings Date||Oct 23, 2023 - Oct 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||333.66|
Subscribe to Yahoo Finance Plus to view Fair Value for BIIB
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.
Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer’s drugs. But is LLY stock a buy now? Here's what you should know.
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.